small molecule

PONVORY

PONESIMOD

Loss of exclusivityOctober 2042latest FDA-listed patent expiry

CompanyVanda Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	PONVORY
Active ingredient	PONESIMOD
Strength	2MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	March 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
11951097	October 2042	use U-3891
12336980	December 2035	use U-3103
10220023	December 2035	use U-3103
9062014	May 2032	substance, product
RE43728	November 2029	substance, product

Regulatory exclusivity

Code	Expires
NCE	March 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Vanda Pharmaceuticals